{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:17:50Z","timestamp":1779297470879,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160034"],"award-info":[{"award-number":["82160034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Program of Xinjiang Uygur Autonomous Region","award":["2022D14008"],"award-info":[{"award-number":["2022D14008"]}]},{"name":"the Tianshan Medical and Health Talents Training Program of Xinjiang Uygur Autonomous Region","award":["TSYC202301A006"],"award-info":[{"award-number":["TSYC202301A006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04082-4","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T11:29:39Z","timestamp":1748604579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9"],"prefix":"10.1007","volume":"74","author":[{"given":"Ruixue","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejiao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xierenguli","family":"Alimu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"4082_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/intimm\/dxr027","volume":"23","author":"L Kardava","year":"2011","unstructured":"Kardava L, Yang Q, St Leger A, Foon KA, Lentzsch S, Vallejo AN, Milcarek C, Borghesi L (2011) The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells. Int Immunol 23:375\u2013384. https:\/\/doi.org\/10.1093\/intimm\/dxr027","journal-title":"Int Immunol"},{"key":"4082_CR2","doi-asserted-by":"publisher","first-page":"11573","DOI":"10.3389\/bjbs.2023.11573","volume":"80","author":"HK Al-Zubaidi","year":"2023","unstructured":"Al-Zubaidi HK, Hughes SF (2023) The use of CD200 in the differential diagnosis of B-cell lymphoproliferative disorders. Br J Biomed Sci 80:11573. https:\/\/doi.org\/10.3389\/bjbs.2023.11573","journal-title":"Br J Biomed Sci"},{"key":"4082_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","volume":"104","author":"L Scarfo","year":"2016","unstructured":"Scarfo L, Ferreri AJ, Ghia P (2016) Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol 104:169\u2013182. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.06.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"4082_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M (2023) Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA 329:918\u2013932. https:\/\/doi.org\/10.1001\/jama.2023.1946","journal-title":"JAMA"},{"key":"4082_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11899-023-00700-z","volume":"18","author":"O Odetola","year":"2023","unstructured":"Odetola O, Ma S (2023) Relapsed\/refractory chronic lymphocytic leukemia (CLL). Curr Hematol Malig Rep 18:130\u2013143. https:\/\/doi.org\/10.1007\/s11899-023-00700-z","journal-title":"Curr Hematol Malig Rep"},{"key":"4082_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR et al (2023) Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 389:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696","journal-title":"N Engl J Med"},{"key":"4082_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS et al (2023) Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet 402:641\u2013654. https:\/\/doi.org\/10.1016\/S0140-6736(23)01052-8","journal-title":"Lancet"},{"key":"4082_CR8","doi-asserted-by":"publisher","first-page":"8871037","DOI":"10.1155\/2022\/8871037","volume":"2022","author":"LL Mi","year":"2022","unstructured":"Mi LL, Guo WW (2022) Crosstalk between ILC2s and Th2 CD4(+) T cells in lung disease. J Immunol Res 2022:8871037. https:\/\/doi.org\/10.1155\/2022\/8871037","journal-title":"J Immunol Res"},{"key":"4082_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ni.3309","volume":"17","author":"K Moro","year":"2016","unstructured":"Moro K, Kabata H, Tanabe M et al (2016) Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat Immunol 17:76\u201386. https:\/\/doi.org\/10.1038\/ni.3309","journal-title":"Nat Immunol"},{"key":"4082_CR10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier E, Artis D, Colonna M et al (2018) Innate lymphoid cells: 10 years On. Cell 174:1054\u20131066. https:\/\/doi.org\/10.1016\/j.cell.2018.07.017","journal-title":"Cell"},{"key":"4082_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030559","author":"Q Huang","year":"2021","unstructured":"Huang Q, Jacquelot N, Preaudet A et al (2021) Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13030559","journal-title":"Cancers (Basel)"},{"key":"4082_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","volume":"579","author":"JA Moral","year":"2020","unstructured":"Moral JA, Leung J, Rojas LA et al (2020) ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature 579:130\u2013135. https:\/\/doi.org\/10.1038\/s41586-020-2015-4","journal-title":"Nature"},{"key":"4082_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/ijc.28481","volume":"134","author":"IP Jovanovic","year":"2014","unstructured":"Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML (2014) Interleukin-33\/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 134:1669\u20131682. https:\/\/doi.org\/10.1002\/ijc.28481","journal-title":"Int J Cancer"},{"key":"4082_CR14","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41375-020-0843-8","volume":"34","author":"L Wu","year":"2020","unstructured":"Wu L, Lin Q, Ma Z, Chowdhury FA, Mazumder MHH, Du W (2020) Mesenchymal PGD(2) activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia 34:3028\u20133041. https:\/\/doi.org\/10.1038\/s41375-020-0843-8","journal-title":"Leukemia"},{"key":"4082_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2021.01.002","volume":"502","author":"J Wan","year":"2021","unstructured":"Wan J, Wu Y, Huang L et al (2021) ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8(+) T cells. Cancer Lett 502:34\u201343. https:\/\/doi.org\/10.1016\/j.canlet.2021.01.002","journal-title":"Cancer Lett"},{"key":"4082_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2022.10.002","volume":"174","author":"Y Feng","year":"2022","unstructured":"Feng Y, Yan S, Lam SK, Ko FCF, Chen C, Khan M, Ho JC (2022) IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model. Lung Cancer 174:14\u201326. https:\/\/doi.org\/10.1016\/j.lungcan.2022.10.002","journal-title":"Lung Cancer"},{"key":"4082_CR17","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2147\/ott.S197816","volume":"12","author":"L Cai","year":"2019","unstructured":"Cai L, Zhang Y, Zhang Y, Chen H, Hu J (2019) Effect of Th9\/IL-9 on the growth of gastric cancer in nude mice. Onco Targets Ther 12:2225\u20132234. https:\/\/doi.org\/10.2147\/ott.S197816","journal-title":"Onco Targets Ther"},{"key":"4082_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood-2006-04-020305","volume":"108","author":"L Qiu","year":"2006","unstructured":"Qiu L, Lai R, Lin Q et al (2006) Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108:2407\u20132415. https:\/\/doi.org\/10.1182\/blood-2006-04-020305","journal-title":"Blood"},{"key":"4082_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004418","volume":"10","author":"A Lavorgna","year":"2014","unstructured":"Lavorgna A, Matsuoka M, Harhaj EW (2014) A critical role for IL-17RB signaling in HTLV-1 tax-induced NF-\u03baB activation and T-cell transformation. PLoS Pathog 10:e1004418. https:\/\/doi.org\/10.1371\/journal.ppat.1004418","journal-title":"PLoS Pathog"},{"key":"4082_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaci.2020.05.042","volume":"146","author":"KJ Cavagnero","year":"2020","unstructured":"Cavagnero KJ, Doherty TA (2020) ILC2s: Are they what we think they are? J Allergy Clin Immunol 146:280\u2013282. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.042","journal-title":"J Allergy Clin Immunol"},{"key":"4082_CR21","doi-asserted-by":"publisher","first-page":"1260859","DOI":"10.3389\/fimmu.2023.1260859","volume":"14","author":"P Sankar","year":"2023","unstructured":"Sankar P, Mishra BB (2023) Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis. Front Immunol 14:1260859. https:\/\/doi.org\/10.3389\/fimmu.2023.1260859","journal-title":"Front Immunol"},{"key":"4082_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100870","volume":"80","author":"S Sivori","year":"2021","unstructured":"Sivori S, Pende D, Quatrini L et al (2021) NK cells and ILCs in tumor immunotherapy. Mol Aspects Med 80:100870. https:\/\/doi.org\/10.1016\/j.mam.2020.100870","journal-title":"Mol Aspects Med"},{"key":"4082_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108620","volume":"222","author":"K Domvri","year":"2021","unstructured":"Domvri K, Petanidis S, Zarogoulidis P et al (2021) Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING\/ILC2 axis. Clin Immunol 222:108620. https:\/\/doi.org\/10.1016\/j.clim.2020.108620","journal-title":"Clin Immunol"},{"key":"4082_CR24","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41590-020-0745-y","volume":"21","author":"MJ Schuijs","year":"2020","unstructured":"Schuijs MJ, Png S, Richard AC et al (2020) ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat Immunol 21:998\u20131009. https:\/\/doi.org\/10.1038\/s41590-020-0745-y","journal-title":"Nat Immunol"},{"key":"4082_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","volume":"8","author":"S Trabanelli","year":"2017","unstructured":"Trabanelli S, Chevalier MF, Martinez-Usatorre A et al (2017) Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun 8:593. https:\/\/doi.org\/10.1038\/s41467-017-00678-2","journal-title":"Nat Commun"},{"key":"4082_CR26","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.4049\/jimmunol.1003049","volume":"186","author":"R Goswami","year":"2011","unstructured":"Goswami R, Kaplan MH (2011) A brief history of IL-9. J Immunol 186:3283\u20133288. https:\/\/doi.org\/10.4049\/jimmunol.1003049","journal-title":"J Immunol"},{"key":"4082_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12964-020-00538-5","volume":"18","author":"J Wan","year":"2020","unstructured":"Wan J, Wu Y, Ji X, Huang L, Cai W, Su Z, Wang S, Xu H (2020) IL-9 and IL-9-producing cells in tumor immunity. Cell Commun Signal 18:50. https:\/\/doi.org\/10.1186\/s12964-020-00538-5","journal-title":"Cell Commun Signal"},{"key":"4082_CR28","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.3390\/cancers13246301","volume":"13","author":"L Patrussi","year":"2021","unstructured":"Patrussi L, Capitani N, Baldari CT (2021) Interleukin (IL)-9 supports the tumor-promoting environment of chronic lymphocytic leukemia. Cancers (Basel) 13:6301. https:\/\/doi.org\/10.3390\/cancers13246301","journal-title":"Cancers (Basel)"},{"key":"4082_CR29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ccell.2018.05.004","volume":"33","author":"Y Lu","year":"2018","unstructured":"Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A, Qian J, Dong C, Yi Q (2018) Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors. Cancer Cell 33:1048\u201360.e7. https:\/\/doi.org\/10.1016\/j.ccell.2018.05.004","journal-title":"Cancer Cell"},{"key":"4082_CR30","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e12","volume":"18","author":"VA Do Thi","year":"2018","unstructured":"Do Thi VA, Park SM, Lee H, Kim YS (2018) Ectopically expressed membrane-bound form of IL-9 exerts immune-stimulatory effect on CT26 colon carcinoma cells. Immune Netw 18:e12. https:\/\/doi.org\/10.4110\/in.2018.18.e12","journal-title":"Immune Netw"},{"key":"4082_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.intimp.2017.08.031","volume":"52","author":"FP You","year":"2017","unstructured":"You FP, Zhang J, Cui T, Zhu R, Lv CQ, Tang HT, Sun DW (2017) Th9 cells promote antitumor immunity via IL-9 and IL-21 and demonstrate atypical cytokine expression in breast cancer. Int Immunopharmacol 52:163\u2013167. https:\/\/doi.org\/10.1016\/j.intimp.2017.08.031","journal-title":"Int Immunopharmacol"},{"key":"4082_CR32","first-page":"911","volume":"6","author":"X Lv","year":"2013","unstructured":"Lv X, Feng L, Fang X, Jiang Y, Wang X (2013) Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol 6:911\u2013916","journal-title":"Int J Clin Exp Pathol"},{"key":"4082_CR33","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1084\/jem.20130071","volume":"210","author":"JE Turner","year":"2013","unstructured":"Turner JE, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld JC, Panzer U, Helmby H, Stockinger B (2013) IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med 210:2951\u20132965. https:\/\/doi.org\/10.1084\/jem.20130071","journal-title":"J Exp Med"},{"key":"4082_CR34","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100013R","volume":"35","author":"N Pang","year":"2021","unstructured":"Pang N, Alimu X, Chen R et al (2021) Activated Galectin-9\/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. Faseb j 35:e21556. https:\/\/doi.org\/10.1096\/fj.202100013R","journal-title":"Faseb j"},{"key":"4082_CR35","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS (2019) T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol 10:2453. https:\/\/doi.org\/10.3389\/fimmu.2019.02453","journal-title":"Front Immunol"},{"key":"4082_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00923.x","journal-title":"Immunol Rev"},{"key":"4082_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790963","volume":"12","author":"V Singh","year":"2021","unstructured":"Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R (2021) Emerging role of PD-1\/PD-L1 inhibitors in chronic liver diseases. Front Pharmacol 12:790963. https:\/\/doi.org\/10.3389\/fphar.2021.790963","journal-title":"Front Pharmacol"},{"key":"4082_CR38","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, Munger ME, Highfill SL et al (2010) Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116:2484\u20132493. https:\/\/doi.org\/10.1182\/blood-2010-03-275446","journal-title":"Blood"},{"key":"4082_CR39","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/eji.201344423","volume":"44","author":"X Chen","year":"2014","unstructured":"Chen X, Fosco D, Kline DE, Meng L, Nishi S, Savage PA, Kline J (2014) PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol 44:2603\u20132616. https:\/\/doi.org\/10.1002\/eji.201344423","journal-title":"Eur J Immunol"},{"key":"4082_CR40","doi-asserted-by":"publisher","first-page":"9331","DOI":"10.1073\/pnas.0710441105","volume":"105","author":"L Wang","year":"2008","unstructured":"Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A 105:9331\u20139336. https:\/\/doi.org\/10.1073\/pnas.0710441105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4082_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091277","author":"A Rotte","year":"2021","unstructured":"Rotte A, Sahasranaman S, Budha N (2021) Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9091277","journal-title":"Biomedicines"},{"key":"4082_CR42","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1172\/jci81187","volume":"125","author":"S Kurtulus","year":"2015","unstructured":"Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC (2015) TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125:4053\u20134062. https:\/\/doi.org\/10.1172\/jci81187","journal-title":"J Clin Invest"},{"key":"4082_CR43","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J et al (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:923\u2013937. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.018","journal-title":"Cancer Cell"},{"key":"4082_CR44","first-page":"2319","volume":"7","author":"N Chen","year":"2014","unstructured":"Chen N, Lu K, Li P, Lv X, Wang X (2014) Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol 7:2319\u20132323","journal-title":"Int J Clin Exp Pathol"},{"key":"4082_CR45","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.4049\/jimmunol.174.4.2124","volume":"174","author":"PA Revell","year":"2005","unstructured":"Revell PA, Grossman WJ, Thomas DA, Cao X, Behl R, Ratner JA, Lu ZH, Ley TJ (2005) Granzyme B and the downstream granzymes C and\/or F are important for cytotoxic lymphocyte functions. J Immunol 174:2124\u20132131. https:\/\/doi.org\/10.4049\/jimmunol.174.4.2124","journal-title":"J Immunol"},{"key":"4082_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.21037\/tcr-21-2506","volume":"11","author":"JH Chung","year":"2022","unstructured":"Chung JH, Ha JS, Choi J, Kwon SM, Yun MS, Kim T, Jeon D, Yoon SH, Kim YS (2022) Granzyme B for predicting the durable clinical benefit of anti-PD-1\/PD-L1 immunotherapy in patients with non-small cell lung cancer. Transl Cancer Res 11:316\u2013326. https:\/\/doi.org\/10.21037\/tcr-21-2506","journal-title":"Transl Cancer Res"},{"key":"4082_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imr.12706","volume":"286","author":"H Kabata","year":"2018","unstructured":"Kabata H, Moro K, Koyasu S (2018) The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms. Immunol Rev 286:37\u201352. https:\/\/doi.org\/10.1111\/imr.12706","journal-title":"Immunol Rev"},{"key":"4082_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482","author":"AK Abbas","year":"2018","unstructured":"Abbas AK, Trotta E, D RS, Marson A, Bluestone JA, (2018) Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aat1482","journal-title":"Sci Immunol"},{"key":"4082_CR49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Vieira P, O\u2019Garra A (2020) Biology and therapeutic potential of interleukin-10. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20190418","journal-title":"J Exp Med"},{"key":"4082_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022061","author":"A Hata","year":"2016","unstructured":"Hata A, Chen YG (2016) TGF-beta Signaling from Receptors to Smads. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a022061","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4082_CR51","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1159\/000443067","volume":"38","author":"A Gassa","year":"2016","unstructured":"Gassa A, Jian F, Kalkavan H et al (2016) IL-10 induces T cell exhaustion during transplantation of virus infected hearts. Cell Physiol Biochem 38:1171\u20131181. https:\/\/doi.org\/10.1159\/000443067","journal-title":"Cell Physiol Biochem"},{"key":"4082_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369\u2013380. https:\/\/doi.org\/10.1016\/j.ccr.2005.10.012","journal-title":"Cancer Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04082-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:15:53Z","timestamp":1749896153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04082-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4082"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04082-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (approval no. 20211015\u201347).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"228"}}